

Table 14.2-2.81: Summary of Slit Lamp Examination Grade (Full Analysis Set)

| Eye Structure | Visit | Score | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|---------------------------|-----------------------------------|--|---------------------------------------|-------------------------------------|----------------------------|----------------------------|
| Eyelid - Meibomian glands | Screening | 0 – None (none are plugged) | 7 (24.1) | 13 (43.3) | 5 (16.7) | 25 (28.1) |
| | | 1 – Mild (1 to 2 glands are plugged) | 7 (24.1) | 4 (13.3) | 1 (3.3) | 12 (13.5) |
| | | 2 – Moderate (3 to 4 glands are plugged) | 14 (48.3) | 4 (13.3) | 15 (50.0) | 33 (37.1) |
| | | 3 – Severe (all glands are plugged) | 1 (3.4) | 9 (30.0) | 9 (30.0) | 19 (21.3) |
| | Randomization, pre-randomization | 0 – None (none are plugged) | 7 (24.1) | 13 (43.3) | 5 (16.7) | 25 (28.1) |
| | | 1 – Mild (1 to 2 glands are plugged) | 8 (27.6) | 5 (16.7) | 3 (10.0) | 16 (18.0) |
| | | 2 – Moderate (3 to 4 glands are plugged) | 10 (34.5) | 5 (16.7) | 15 (50.0) | 30 (33.7) |
| | | 3 – Severe (all glands are plugged) | 4 (13.8) | 7 (23.3) | 7 (23.3) | 18 (20.2) |
| | Randomization, post-randomization | 0 – None (none are plugged) | 7 (25.0) | 13 (43.3) | 5 (16.7) | 25 (28.4) |
| | | 1 – Mild (1 to 2 glands are plugged) | 7 (25.0) | 6 (20.0) | 2 (6.7) | 15 (17.0) |
| | | 2 – Moderate (3 to 4 glands are plugged) | 14 (50.0) | 7 (23.3) | 17 (56.7) | 38 (43.2) |
| | | 3 – Severe (all glands are plugged) | — | 4 (13.3) | 6 (20.0) | 10 (11.4) |
| | | Missing | 1 | — | — | 1 |
| | Week 2 | 0 – None (none are plugged) | 8 (28.6) | 11 (39.3) | 6 (20.0) | 25 (29.1) |
| | | 1 – Mild (1 to 2 glands are plugged) | 12 (42.9) | 10 (35.7) | 5 (16.7) | 27 (31.4) |
| | | 2 – Moderate (3 to 4 glands are plugged) | 8 (28.6) | 7 (25.0) | 17 (56.7) | 32 (37.2) |
| | | 3 – Severe (all glands are plugged) | — | — | 2 (6.7) | 2 (2.3) |
| | | Missing | 1 | — | — | 1 |

Table 14.2-2.81: Summary of Slit Lamp Examination Grade (Full Analysis Set)

| Eye Structure | Visit | Score | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|---------------------------|---------|--|---------------------------------------|-------------------------------------|----------------------------|----------------------------|
| Eyelid - Meibomian glands | Week 4 | 0 – None (none are plugged) | 10 (35.7) | 12 (41.4) | 6 (20.0) | 28 (32.2) |
| | | 1 – Mild (1 to 2 glands are plugged) | 13 (46.4) | 9 (31.0) | 12 (40.0) | 34 (39.1) |
| | | 2 – Moderate (3 to 4 glands are plugged) | 5 (17.9) | 8 (27.6) | 11 (36.7) | 24 (27.6) |
| | | 3 – Severe (all glands are plugged) | — | — | 1 (3.3) | 1 (1.1) |
| | | Missing | 1 | — | — | 1 |
| | Week 8 | 0 – None (none are plugged) | 8 (33.3) | 13 (46.4) | 7 (25.0) | 28 (35.0) |
| | | 1 – Mild (1 to 2 glands are plugged) | 9 (37.5) | 4 (14.3) | 9 (32.1) | 22 (27.5) |
| | | 2 – Moderate (3 to 4 glands are plugged) | 6 (25.0) | 8 (28.6) | 11 (39.3) | 25 (31.3) |
| | | 3 – Severe (all glands are plugged) | 1 (4.2) | 3 (10.7) | 1 (3.6) | 5 (6.3) |
| | | Missing | 3 | 1 | — | 4 |
| | Week 12 | 0 – None (none are plugged) | 10 (40.0) | 12 (42.9) | 5 (18.5) | 27 (33.8) |
| | | 1 – Mild (1 to 2 glands are plugged) | 10 (40.0) | 8 (28.6) | 10 (37.0) | 28 (35.0) |
| | | 2 – Moderate (3 to 4 glands are plugged) | 5 (20.0) | 7 (25.0) | 12 (44.4) | 24 (30.0) |
| | | 3 – Severe (all glands are plugged) | — | 1 (3.6) | — | 1 (1.3) |
| | | Missing | 1 | — | — | 1 |

Table 14.2-2.81: Summary of Slit Lamp Examination Grade (Full Analysis Set)

| Eye Structure | Visit | Score | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|---------------------------|---------------------|--|---------------------------------------|-------------------------------------|----------------------------|----------------------------|
| Eyelid - Meibomian glands | Week 16 (Follow Up) | 0 – None (none are plugged) | 8 (33.3) | 12 (44.4) | 4 (15.4) | 24 (31.2) |
| | | 1 – Mild (1 to 2 glands are plugged) | 12 (50.0) | 8 (29.6) | 11 (42.3) | 31 (40.3) |
| | | 2 – Moderate (3 to 4 glands are plugged) | 4 (16.7) | 5 (18.5) | 9 (34.6) | 18 (23.4) |
| | | 3 – Severe (all glands are plugged) | — | 2 (7.4) | 2 (7.7) | 4 (5.2) |
| | | Missing | 2 | — | — | 2 |
| | Early Termination | 0 – None (none are plugged) | 1 (100.0) | 1 (100.0) | 1 (100.0) | 3 (100.0) |
| | | 1 – Mild (1 to 2 glands are plugged) | — | — | — | — |
| | | 2 – Moderate (3 to 4 glands are plugged) | — | — | — | — |
| | | 3 – Severe (all glands are plugged) | — | — | — | — |
| | | Missing | 9 | 4 | 5 | 18 |

Table 14.2-2.81: Summary of Slit Lamp Examination Grade (Full Analysis Set)

| Eye Structure | Visit | Score | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|-------------------|-----------------------------------|---|---------------------------------------|-------------------------------------|----------------------------|----------------------------|
| Eyelid - Erythema | Screening | 0 – None (normal) | 8 (27.6) | 14 (46.7) | 5 (16.7) | 27 (30.3) |
| | | 1 – Mild (redness localized to a small region of the lid(s) margin or skin) | 13 (44.8) | 7 (23.3) | 6 (20.0) | 26 (29.2) |
| | | 2 – Moderate (redness of most or all lid margin or skin) | 8 (27.6) | 3 (10.0) | 12 (40.0) | 23 (25.8) |
| | | 3 – Severe (redness of most or all lid margin and skin) | — | 6 (20.0) | 5 (16.7) | 11 (12.4) |
| | | 4 – Very severe (marked diffuse redness of both lid margin and skin) | — | — | 2 (6.7) | 2 (2.2) |
| | Randomization, pre-randomization | 0 – None (normal) | 7 (24.1) | 14 (46.7) | 5 (16.7) | 26 (29.2) |
| | | 1 – Mild (redness localized to a small region of the lid(s) margin or skin) | 10 (34.5) | 5 (16.7) | 9 (30.0) | 24 (27.0) |
| | | 2 – Moderate (redness of most or all lid margin or skin) | 8 (27.6) | 5 (16.7) | 11 (36.7) | 24 (27.0) |
| | | 3 – Severe (redness of most or all lid margin and skin) | 4 (13.8) | 6 (20.0) | 4 (13.3) | 14 (15.7) |
| | | 4 – Very severe (marked diffuse redness of both lid margin and skin) | — | — | 1 (3.3) | 1 (1.1) |
| | Randomization, post-randomization | 0 – None (normal) | 7 (25.0) | 14 (46.7) | 5 (16.7) | 26 (29.5) |
| | | 1 – Mild (redness localized to a small region of the lid(s) margin or skin) | 13 (46.4) | 4 (13.3) | 8 (26.7) | 25 (28.4) |
| | | 2 – Moderate (redness of most or all lid margin or skin) | 6 (21.4) | 6 (20.0) | 12 (40.0) | 24 (27.3) |
| | | 3 – Severe (redness of most or all lid margin and skin) | 2 (7.1) | 6 (20.0) | 4 (13.3) | 12 (13.6) |
| | | 4 – Very severe (marked diffuse redness of both lid margin and skin) | — | — | 1 (3.3) | 1 (1.1) |
| | | Missing | 1 | — | — | 1 |

Table 14.2-2.81: Summary of Slit Lamp Examination Grade (Full Analysis Set)

| Eye Structure | Visit | Score | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|-------------------|--------|---|---------------------------------------|-------------------------------------|----------------------------|----------------------------|
| Eyelid - Erythema | Week 2 | 0 – None (normal) | 13 (46.4) | 13 (46.4) | 8 (26.7) | 34 (39.5) |
| | | 1 – Mild (redness localized to a small region of the lid(s) margin or skin) | 12 (42.9) | 9 (32.1) | 13 (43.3) | 34 (39.5) |
| | | 2 – Moderate (redness of most or all lid margin or skin) | 3 (10.7) | 4 (14.3) | 7 (23.3) | 14 (16.3) |
| | | 3 – Severe (redness of most or all lid margin and skin) | — | 2 (7.1) | 1 (3.3) | 3 (3.5) |
| | | 4 – Very severe (marked diffuse redness of both lid margin and skin) | — | — | 1 (3.3) | 1 (1.2) |
| | | Missing | 1 | — | — | 1 |
| | Week 4 | 0 – None (normal) | 12 (42.9) | 13 (44.8) | 8 (26.7) | 33 (37.9) |
| | | 1 – Mild (redness localized to a small region of the lid(s) margin or skin) | 14 (50.0) | 12 (41.4) | 14 (46.7) | 40 (46.0) |
| | | 2 – Moderate (redness of most or all lid margin or skin) | 2 (7.1) | 4 (13.8) | 6 (20.0) | 12 (13.8) |
| | | 3 – Severe (redness of most or all lid margin and skin) | — | — | 2 (6.7) | 2 (2.3) |
| | | 4 – Very severe (marked diffuse redness of both lid margin and skin) | — | — | — | — |
| | | Missing | 1 | — | — | 1 |
| | Week 8 | 0 – None (normal) | 10 (41.7) | 14 (50.0) | 9 (32.1) | 33 (41.3) |
| | | 1 – Mild (redness localized to a small region of the lid(s) margin or skin) | 11 (45.8) | 10 (35.7) | 11 (39.3) | 32 (40.0) |
| | | 2 – Moderate (redness of most or all lid margin or skin) | 3 (12.5) | 3 (10.7) | 8 (28.6) | 14 (17.5) |
| | | 3 – Severe (redness of most or all lid margin and skin) | — | 1 (3.6) | — | 1 (1.3) |
| | | 4 – Very severe (marked diffuse redness of both lid margin and skin) | — | — | — | — |
| | | Missing | 3 | 1 | — | 4 |

Table 14.2-2.81: Summary of Slit Lamp Examination Grade (Full Analysis Set)

| Eye Structure | Visit | Score | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|-------------------|---------------------|---|---------------------------------------|-------------------------------------|----------------------------|----------------------------|
| Eyelid - Erythema | Week 12 | 0 – None (normal) | 11 (44.0) | 13 (46.4) | 10 (37.0) | 34 (42.5) |
| | | 1 – Mild (redness localized to a small region of the lid(s) margin or skin) | 11 (44.0) | 11 (39.3) | 11 (40.7) | 33 (41.3) |
| | | 2 – Moderate (redness of most or all lid margin or skin) | 3 (12.0) | 3 (10.7) | 5 (18.5) | 11 (13.8) |
| | | 3 – Severe (redness of most or all lid margin and skin) | — | 1 (3.6) | 1 (3.7) | 2 (2.5) |
| | | 4 – Very severe (marked diffuse redness of both lid margin and skin) | — | — | — | — |
| | | Missing | 1 | — | — | 1 |
| | Week 16 (Follow Up) | 0 – None (normal) | 8 (33.3) | 12 (44.4) | 5 (19.2) | 25 (32.5) |
| | | 1 – Mild (redness localized to a small region of the lid(s) margin or skin) | 12 (50.0) | 11 (40.7) | 13 (50.0) | 36 (46.8) |
| | | 2 – Moderate (redness of most or all lid margin or skin) | 4 (16.7) | 3 (11.1) | 8 (30.8) | 15 (19.5) |
| | | 3 – Severe (redness of most or all lid margin and skin) | — | — | — | — |
| | | 4 – Very severe (marked diffuse redness of both lid margin and skin) | — | 1 (3.7) | — | 1 (1.3) |
| | | Missing | 2 | — | — | 2 |
| | Early Termination | 0 – None (normal) | 1 (100.0) | 1 (100.0) | 1 (100.0) | 3 (100.0) |
| | | 1 – Mild (redness localized to a small region of the lid(s) margin or skin) | — | — | — | — |
| | | 2 – Moderate (redness of most or all lid margin or skin) | — | — | — | — |
| | | 3 – Severe (redness of most or all lid margin and skin) | — | — | — | — |
| | | 4 – Very severe (marked diffuse redness of both lid margin and skin) | — | — | — | — |
| | | Missing | 9 | 4 | 5 | 18 |

Table 14.2-2.81: Summary of Slit Lamp Examination Grade (Full Analysis Set)

| Eye Structure | Visit | Score | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|----------------|-----------------------------------|---|---------------------------------------|-------------------------------------|----------------------------|----------------------------|
| Eyelid - Edema | Screening | 0 – None (normal) | 19 (65.5) | 19 (63.3) | 10 (33.3) | 48 (53.9) |
| | | 1 – Mild (localized to a small region of the lid) | 7 (24.1) | 4 (13.3) | 6 (20.0) | 17 (19.1) |
| | | 2 – Moderate (diffuse, most or all lid and prominent/protruding) | 3 (10.3) | 5 (16.7) | 10 (33.3) | 18 (20.2) |
| | | 3 – Severe (diffuse, most or all lid and prominent/protruding) | — | 2 (6.7) | 4 (13.3) | 6 (6.7) |
| | | 4 – Very severe (diffuse and prominent/protruding and reversion of the lid) | — | — | — | — |
| | Randomization, pre-randomization | 0 – None (normal) | 16 (55.2) | 19 (63.3) | 10 (33.3) | 45 (50.6) |
| | | 1 – Mild (localized to a small region of the lid) | 4 (13.8) | 2 (6.7) | 7 (23.3) | 13 (14.6) |
| | | 2 – Moderate (diffuse, most or all lid and prominent/protruding) | 7 (24.1) | 6 (20.0) | 13 (43.3) | 26 (29.2) |
| | | 3 – Severe (diffuse, most or all lid and prominent/protruding) | 2 (6.9) | 3 (10.0) | — | 5 (5.6) |
| | | 4 – Very severe (diffuse and prominent/protruding and reversion of the lid) | — | — | — | — |
| | Randomization, post-randomization | 0 – None (normal) | 16 (57.1) | 18 (60.0) | 10 (33.3) | 44 (50.0) |
| | | 1 – Mild (localized to a small region of the lid) | 6 (21.4) | 2 (6.7) | 7 (23.3) | 15 (17.0) |
| | | 2 – Moderate (diffuse, most or all lid and prominent/protruding) | 5 (17.9) | 7 (23.3) | 12 (40.0) | 24 (27.3) |
| | | 3 – Severe (diffuse, most or all lid and prominent/protruding) | 1 (3.6) | 3 (10.0) | 1 (3.3) | 5 (5.7) |
| | | 4 – Very severe (diffuse and prominent/protruding and reversion of the lid) | — | — | — | — |
| | | Missing | 1 | — | — | 1 |

Table 14.2-2.81: Summary of Slit Lamp Examination Grade (Full Analysis Set)

| Eye Structure | Visit | Score | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|----------------|--------|---|---------------------------------------|-------------------------------------|----------------------------|----------------------------|
| Eyelid - Edema | Week 2 | 0 – None (normal) | 24 (85.7) | 18 (64.3) | 13 (43.3) | 55 (64.0) |
| | | 1 – Mild (localized to a small region of the lid) | 3 (10.7) | 6 (21.4) | 10 (33.3) | 19 (22.1) |
| | | 2 – Moderate (diffuse, most or all lid and prominent/protruding) | 1 (3.6) | 4 (14.3) | 7 (23.3) | 12 (14.0) |
| | | 3 – Severe (diffuse, most or all lid and prominent/protruding) | — | — | — | — |
| | | 4 – Very severe (diffuse and prominent/protruding and reversion of the lid) | — | — | — | — |
| | | Missing | 1 | — | — | 1 |
| | Week 4 | 0 – None (normal) | 25 (89.3) | 19 (65.5) | 13 (43.3) | 57 (65.5) |
| | | 1 – Mild (localized to a small region of the lid) | 2 (7.1) | 6 (20.7) | 11 (36.7) | 19 (21.8) |
| | | 2 – Moderate (diffuse, most or all lid and prominent/protruding) | 1 (3.6) | 4 (13.8) | 5 (16.7) | 10 (11.5) |
| | | 3 – Severe (diffuse, most or all lid and prominent/protruding) | — | — | 1 (3.3) | 1 (1.1) |
| | | 4 – Very severe (diffuse and prominent/protruding and reversion of the lid) | — | — | — | — |
| | | Missing | 1 | — | — | 1 |
| | Week 8 | 0 – None (normal) | 20 (83.3) | 19 (67.9) | 14 (50.0) | 53 (66.3) |
| | | 1 – Mild (localized to a small region of the lid) | 3 (12.5) | 6 (21.4) | 12 (42.9) | 21 (26.3) |
| | | 2 – Moderate (diffuse, most or all lid and prominent/protruding) | 1 (4.2) | 3 (10.7) | 1 (3.6) | 5 (6.3) |
| | | 3 – Severe (diffuse, most or all lid and prominent/protruding) | — | — | 1 (3.6) | 1 (1.3) |
| | | 4 – Very severe (diffuse and prominent/protruding and reversion of the lid) | — | — | — | — |
| | | Missing | 3 | 1 | — | 4 |

Table 14.2-2.81: Summary of Slit Lamp Examination Grade (Full Analysis Set)

| Eye Structure | Visit | Score | Pro-ocular 0.5% (N=29) n (%) | Pro-ocular 1% (N=30) n (%) | Placebo (N=30) n (%) | Overall (N=89) n (%) |
|----------------|---------------------|---|---------------------------------------|-------------------------------------|----------------------------|----------------------------|
| Eyelid - Edema | Week 12 | 0 – None (normal) | 21 (84.0) | 19 (67.9) | 13 (48.1) | 53 (66.3) |
| | | 1 – Mild (localized to a small region of the lid) | 3 (12.0) | 5 (17.9) | 11 (40.7) | 19 (23.8) |
| | | 2 – Moderate (diffuse, most or all lid and prominent/protruding) | 1 (4.0) | 4 (14.3) | 3 (11.1) | 8 (10.0) |
| | | 3 – Severe (diffuse, most or all lid and prominent/protruding) | — | — | — | — |
| | | 4 – Very severe (diffuse and prominent/protruding and reversion of the lid) | — | — | — | — |
| | | Missing | 1 | — | — | 1 |
| | Week 16 (Follow Up) | 0 – None (normal) | 18 (75.0) | 18 (66.7) | 10 (38.5) | 46 (59.7) |
| | | 1 – Mild (localized to a small region of the lid) | 4 (16.7) | 3 (11.1) | 11 (42.3) | 18 (23.4) |
| | | 2 – Moderate (diffuse, most or all lid and prominent/protruding) | 2 (8.3) | 5 (18.5) | 5 (19.2) | 12 (15.6) |
| | | 3 – Severe (diffuse, most or all lid and prominent/protruding) | — | 1 (3.7) | — | 1 (1.3) |
| | | 4 – Very severe (diffuse and prominent/protruding and reversion of the lid) | — | — | — | — |
| | | Missing | 2 | — | — | 2 |
| | Early Termination | 0 – None (normal) | 1 (100.0) | 1 (100.0) | 1 (100.0) | 3 (100.0) |
| | | 1 – Mild (localized to a small region of the lid) | — | — | — | — |
| | | 2 – Moderate (diffuse, most or all lid and prominent/protruding) | — | — | — | — |
| | | 3 – Severe (diffuse, most or all lid and prominent/protruding) | — | — | — | — |
| | | 4 – Very severe (diffuse and prominent/protruding and reversion of the lid) | — | — | — | — |
| | | Missing | 9 | 4 | 5 | 18 |

Table 14.2-2.82: Analysis of Slit Lamp Examination Grades (Full Analysis Set)

| Eye structure | Visit | Comparison | p-value |
|---------------------------|---------------------|----------------------------|---------|
| Eyelid - Meibomian glands | Week 2 | 1% Pro-ocular vs Placebo | 0.009 |
| | | 0.5% Pro-ocular vs Placebo | 0.027 |
| | Week 4 | 1% Pro-ocular vs Placebo | 0.106 |
| | | 0.5% Pro-ocular vs Placebo | 0.050 |
| | Week 8 | 1% Pro-ocular vs Placebo | 0.552 |
| | | 0.5% Pro-ocular vs Placebo | 0.369 |
| | Week 12 | 1% Pro-ocular vs Placebo | 0.107 |
| | | 0.5% Pro-ocular vs Placebo | 0.046 |
| | Week 16 (Follow Up) | 1% Pro-ocular vs Placebo | 0.081 |
| | | 0.5% Pro-ocular vs Placebo | 0.019 |
| Eyelid - Erythema | Week 2 | 1% Pro-ocular vs Placebo | 0.243 |
| | | 0.5% Pro-ocular vs Placebo | 0.030 |
| | Week 4 | 1% Pro-ocular vs Placebo | 0.077 |
| | | 0.5% Pro-ocular vs Placebo | 0.038 |

Table 14.2-2.82: Analysis of Slit Lamp Examination Grades (Full Analysis Set)

| Eye structure | Visit | Comparison | p-value |
|-------------------|---------------------|----------------------------|---------|
| Eyelid - Erythema | Week 8 | 1% Pro-ocular vs Placebo | 0.186 |
| | | 0.5% Pro-ocular vs Placebo | 0.262 |
| | Week 12 | 1% Pro-ocular vs Placebo | 0.432 |
| | | 0.5% Pro-ocular vs Placebo | 0.376 |
| | Week 16 (Follow Up) | 1% Pro-ocular vs Placebo | 0.164 |
| | | 0.5% Pro-ocular vs Placebo | 0.215 |
| Eyelid - Edema | Week 2 | 1% Pro-ocular vs Placebo | 0.124 |
| | | 0.5% Pro-ocular vs Placebo | <.001 |
| | Week 4 | 1% Pro-ocular vs Placebo | 0.121 |
| | | 0.5% Pro-ocular vs Placebo | <.001 |
| | Week 8 | 1% Pro-ocular vs Placebo | 0.286 |
| | | 0.5% Pro-ocular vs Placebo | 0.025 |
| | Week 12 | 1% Pro-ocular vs Placebo | 0.327 |
| | | 0.5% Pro-ocular vs Placebo | 0.015 |

Table 14.2-2.82: Analysis of Slit Lamp Examination Grades (Full Analysis Set)

| Eye structure | Visit | Comparison | p-value |
|----------------|---------------------|----------------------------|---------|
| Eyelid - Edema | Week 16 (Follow Up) | 1% Pro-ocular vs Placebo | 0.374 |
| | | 0.5% Pro-ocular vs Placebo | 0.018 |